XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborations - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
May 08, 2020
Jun. 30, 2022
Jan. 31, 2020
Dec. 31, 2018
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Research and development         $ 1,871,000 $ 15,389,000 $ 11,574,000 $ 32,402,000
Deferred revenue, recognized             200,000  
Mosaic Biosciences Inc | Maximum                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Milestone payment related to regulatory and clinical development events $ 4,000,000.0              
ISU Abxis | Amended and Restated License Agreement                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Regulatory and development milestone payment       $ 2,500,000     0  
ISU Abxis | Maximum | Amended and Restated License Agreement                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Milestone payment       19,500,000     0  
Commercial milestone payments       $ 17,000,000.0     0  
Biogen | Collaboration                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Research and development           $ 1,100,000 700,000 $ 2,600,000
Biogen | Exclusive License                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Up-front payments received     $ 15,000,000.0          
Biogen | Termination Agreement                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Forgiveness of accounts receivable, net   $ 600,000     600,000   $ 600,000  
Payments to cash   $ 10,000            
Biogen | Termination Agreement | General and Administrative                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Settlement expense         $ 600,000      
Biogen | Maximum | Exclusive License                
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                
Development and sales milestone payments     $ 340,000,000.0